BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25198900)

  • 1. CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
    Silvestris N; Simone G; Partipilo G; Scarpi E; Lorusso V; Brunetti AE; Maiello E; Paradiso A; Mangia A
    Int J Mol Sci; 2014 Sep; 15(9):15767-77. PubMed ID: 25198900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
    Paradiso A; Xu J; Mangia A; Chiriatti A; Simone G; Zito A; Montemurro S; Giuliani F; Maiello E; Colucci G
    Int J Cancer; 2004 Aug; 111(2):252-8. PubMed ID: 15197779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
    Shaojun C; Li H; Haixin H; Guisheng L
    Cancer Biol Ther; 2018 Mar; 19(3):153-159. PubMed ID: 29261002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
    Kostopoulos I; Karavasilis V; Karina M; Bobos M; Xiros N; Pentheroudakis G; Kafiri G; Papakostas P; Vrettou E; Fountzilas G
    BMC Cancer; 2009 Sep; 9():339. PubMed ID: 19775480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
    Xu JM; Zhu BD; Mangia A; Simone G; Montemurro S; Giuliani F; Maiello E; Colucci G; Paradiso A
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):312-5. PubMed ID: 15996331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
    Zhao J; Li W; Zhu D; Yu Q; Zhang Z; Sun M; Cai S; Zhang W
    Med Oncol; 2014 Jan; 31(1):802. PubMed ID: 24338217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
    Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
    Corsi DC; Ciaparrone M; Zannoni G; Mancini M; Cassano A; Specchia M; Pozzo C; Martini M; Barone C
    Eur J Cancer; 2002 Mar; 38(4):527-34. PubMed ID: 11872345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
    Lin PC; Lin HH; Lin JK; Lin CC; Yang SH; Li AF; Chen WS; Chang SC
    Int J Biol Markers; 2013 Jun; 28(2):182-6. PubMed ID: 23558935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
    J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
    Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
    Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
    De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
    Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
    Ishida H; Shirakawa K; Ohsawa T; Hayashi Y; Okada N; Nakada H; Yokoyama M
    Gan To Kagaku Ryoho; 2005 Sep; 32(9):1295-9. PubMed ID: 16184927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
    Bendardaf R; Lamlum H; Ristamäki R; Korkeila E; Syrjänen K; Pyrhönen S
    Acta Oncol; 2008; 47(6):1046-53. PubMed ID: 17943475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
    Lakshmaiah KC; Chaudhuri T; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(4):631-633. PubMed ID: 30082548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
    Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
    Tsavaris N; Lazaris A; Kosmas C; Gouveris P; Kavantzas N; Kopterides P; Papathomas T; Agrogiannis G; Zorzos H; Kyriakou V; Patsouris E
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):391-8. PubMed ID: 19083133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
    J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.